GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and ...

Blockbuster diabetes and weight loss drugs, known as GLP-1 treatments, could help reduced the rate of overdoses and ...

Both Wegovy and Mounjaro are given as weekly injections via pre-filled pens that can be self-administered into the upper arm, ...

A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...

The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic. If you had come across the ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The U.K. will study whether Lilly's weight loss drug can get people back to work and help tackle long-term sickness ...